BAFNAPH logo

Bafna Pharmaceuticals LTD

BAFNAPH·NSE·
306.35 -6.25 (-2.00%)
Market Cap724.71 Cr
PE Ratio65.32
Volume1,682
Day High - Low306.35 - 306.35
52W High-Low318.50 - 94.77
DocStoX Score
5.1/10
Weak
Fair Value
Sign in to see
ROE
11.46%
Average
P/E
65.32x
Expensive
Debt / Equity
0.39
Moderate
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed

Price performance

52W94.77
318.50
DocStoX take

Supported by risk (7.5) and momentum (7.5), but held back by valuation (0.0). Risk looks strong at 7.5, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence
5.1
/10
Weak
Quality
Modest
ROE 11.5%
Valuation
Expensive
P/E 65.3×
Growth
Steady
Revenue +16.2% 5Y CAGR
Risk
Low risk
D/E 0.39
Momentum
Strong
95% of 52-week range

At a glance

Market Cap
₹725 Cr
52W High / Low
₹319 / ₹95
Dividend Yield
0.00%
Promoter Holding
75.00%
EPS (TTM)
₹4.69
Book Value
₹40.93

Key highlights

  • Profitable in all of the last 5 years
  • Revenue compounding 16% a year
  • Valuation is weak (0.0/10)
  • Expensive at 65× earnings
2 Positives3 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

BAFNA PHARMACEUTICALS LTD peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.